Impact of the IL4I1 Enzyme Expression in Patients With Cutaneous Melanoma: Prognostic Value and/or Role in Resistance to Current Immunotherapy and Targeted Therapy
To characterize and quantify immune cells expressing the Interleukine 4 induced gene 1 (IL4I1) immunosuppressive enzyme in the blood and in tissue of melanoma patients (primary tumor, sentinel lymph nodes and cutaneous metastases). Then, to compare the results obtained in different clinical settings: * in cases of progression of the disease slower or faster compared to the prognosis established by clinical and pathological data * before and after treatments with immunotherapy (anti Programmed Death ligand 1 (anti-PD1) or anti-PD1 and anti Cytotoxic T Lymphocyte associated protein 4 (anti-CTLA-4)) and / or targeted therapies (BRAF inhibitors and /or methyl ethyl ketone (MEK)).
• group 1: patients with primary thin melanoma (Breslow thickness less than or equal to1 mm) monitored for 10 years, having relapsed or not within 10 years after the diagnosis.
‣ patients with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma
⁃ patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study
⁃ patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research
• group 2: patients with primary thick melanoma (Breslow greater than or equal to 3 mm) monitored for 5 years, having relapsed or not within 5 years after diagnosis.
‣ patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma
⁃ patient or patient's family (in case of death) informed of the objectives and modalities of the study and not opposed to participation in the study
⁃ patient or patient's family (in case of death) not opposed to the use of part of the skin sample previously taken for the present research
• group 3: patient with melanoma (stages III or IV inoperable) and who are treated with immunotherapy and / or biotherapy
‣ patient with no other concomitant cancers requiring systemic treatment at the time of diagnosis of primary melanoma and initiation of systemic treatment for melanoma
⁃ patient informed of the objectives and modalities of the study and having given informed and written consent to participate in the study